4746-61-6Relevant articles and documents
ADENOSINE RECEPTOR BINDING COMPOUNDS
-
Paragraph 00417, (2020/02/06)
The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.
Vilsmeier reagent initialed sequential one-pot multicomponent synthesis of N,O-disubstituted glycolamides as dipeptidyl peptidase 4 inhibitors
Lu, Shi-Han,Yen, Wan-Ping,Tsai, Henry J.,Chen, Chien-Shu,Wong, Fung Fuh
, p. 6749 - 6758 (2015/08/24)
A series of N,O-disubstituted glycolamide derivatives have been successfully synthesized through Vilsmeier reagent initialed sequential one-pot multicomponent procedure from α-chloro N-arylacetamides with formamide/PBr3 and acid chloride. The t
Efficient copper(II)-catalyzed transamidation of non-activated primary carboxamides and ureas with amines
Zhang, Min,Imm, Sebastian,Baehn, Sebastian,Neubert, Lorenz,Neumann, Helfried,Beller, Matthias
, p. 3905 - 3909 (2012/06/04)
Amid(e) them all: Primary carboxamides and ureas react with aromatic and aliphatic amines in the presence of a copper catalyst to give a wide range of functionalized amides (see scheme). Copyright
